Trial intelligence / Profile preview

Antineoplastons A10 and AS2-1 in Stage IV Breast Cancer

NCT00003454Phase 2Terminated

Sponsor
Burzynski Research Institute
Start
Mar 1996
Primary completion
Dec 2002
Modality
Peptides, Small Molecules
Countries
1
01

Overview

A Phase 2 trial of antineoplaston A10, antineoplaston AS2-1 in breast cancer, sponsored by Burzynski Research Institute. Started Mar 1996; status: terminated.

02

Drugs

antineoplaston A10antineoplaston AS2-1
03

Conditions

breast cancer

Beyond the preview

Go deeper on NCT00003454.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00003454.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call